Imamura M, Han M, Hashino S, Kobayashi H, Imai K, Kobayashi M, Kobayashi S, Tanaka J, Kasai M, Sakurada K
Third Department of Internal Medicine, Hokkaido University School of Medicine, Japan.
Immunobiology. 1994 Aug;191(1):21-37. doi: 10.1016/S0171-2985(11)80265-2.
Effects of interleukin-6 (IL-6) on hematopoietic progenitor cells were analyzed in murine bone marrow chimeras. When IL-6 was injected into syngeneic [C3H/He-->C3H/He] bone marrow chimeras from day 1 to day 12, the numbers of highly proliferative potential colony-forming units (CFU-HPP) or colony-forming units mix (CFU-Mix) in spleen cells and bone marrow cells increased on day 14 although there was a marked increase in spleen cells but not in bone marrow cells on day 21. The numbers of CFU-HPP increased in spleen cells from allogeneic [BALB/c-->C3H/He] bone marrow chimeras injected with IL-6 on days 14 and 21. In syngeneic bone marrow chimeras, the numbers of colony-forming units granulocyte/macrophage (CFU-GM) and burst colony-forming units (BFU-E) increased similarly to those of CFU-HPP and CFU-Mix on day 14. On day 21, these were mainly increased in spleen cells. In allogeneic bone marrow chimeras, IL-6 decreased the numbers of CFU-GM and BFU-Mix dose-dependently on day 14. Only 10 micrograms of IL-6 increased the numbers of CFU-GM and BFU-E on day 21. In our previous work, we showed that platelet counts increased on day 14 in syngeneic bone marrow chimeras injected with IL-6, whereas platelet and leukocyte counts increased on days 14 and 24 in allogeneic bone marrow chimeras injected with IL-6, correlating inversely with the numbers of hematopoietic progenitor cells. Overall, primitive hematopoietic progenitors (i.e., CFU-HPP and CFU-Mix) existed primarily in spleen cells of allogeneic bone marrow chimeras on day 14, whereas those in spleen cells of syngeneic bone marrow chimeras were found on day 21. These findings indicate that the effect of IL-6 on hematopoiesis in allogeneic bone marrow chimeras is completely different from that in syngeneic bone marrow chimeras, probably via graft-versus-host reaction (GVHR) but not GVH disease (GVHD).
在小鼠骨髓嵌合体中分析了白细胞介素-6（IL-6）对造血祖细胞的影响。从第1天到第12天向同基因[C3H/He→C3H/He]骨髓嵌合体注射IL-6时，脾细胞和骨髓细胞中高增殖潜能集落形成单位（CFU-HPP）或混合集落形成单位（CFU-Mix）的数量在第14天增加，尽管在第21天脾细胞有显著增加而骨髓细胞没有。在第14天和第21天向同种异体[BALB/c→C3H/He]骨髓嵌合体注射IL-6后，脾细胞中CFU-HPP的数量增加。在同基因骨髓嵌合体中，粒细胞/巨噬细胞集落形成单位（CFU-GM）和爆式集落形成单位（BFU-E）的数量在第14天与CFU-HPP和CFU-Mix的数量相似地增加。在第21天，这些主要在脾细胞中增加。在同种异体骨髓嵌合体中，IL-6在第14天剂量依赖性地降低CFU-GM和BFU-Mix的数量。仅10微克IL-6在第21天增加CFU-GM和BFU-E的数量。在我们之前的工作中，我们表明向注射IL-6的同基因骨髓嵌合体中，血小板计数在第14天增加，而向注射IL-6的同种异体骨髓嵌合体中，血小板和白细胞计数在第14天和第24天增加，这与造血祖细胞的数量呈负相关。总体而言，原始造血祖细胞（即CFU-HPP和CFU-Mix）在第14天主要存在于同种异体骨髓嵌合体的脾细胞中，而在同基因骨髓嵌合体的脾细胞中则在第21天发现。这些发现表明IL-6对同种异体骨髓嵌合体造血的影响与同基因骨髓嵌合体中的完全不同，可能是通过移植物抗宿主反应（GVHR）而非移植物抗宿主病（GVHD）。
